Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: Product/Service

Noveome Biotherapeutics, Inc. Receives Rare Pediatric Disease Designation and Orphan Drug Designation for the Treatment of Necrotizing Enterocolitis in Neonates


Noveome Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to the company's lead product ST266 for the treatment of Necrotizing Enterocolitis (NEC).

"NEC is a devastating disease that affects the most vulnerable among us," said Christopher Velis, Chief Executive Officer of Noveome. "We remain motivated by the prospect of providing the first major improvement in lifesaving therapy for infants affected by NEC in over 40 years. These babies, their families, and the doctors and nurses who have devoted their own lives to fighting this disease deserve our collective best efforts to advance our therapy into clinical practice."

The FDA grants RPDD for serious and life-threatening diseases affecting children aged 18 years or younger and ODD for rare diseases that impact fewer than 200,000 people in the United States. ST266 is being evaluated in multiple preclinical animal models and the company is in the planning stages for clinical trials to investigate treatment with ST266 for NEC.

About Necrotizing Enterocolitis (NEC)

Necrotizing Enterocolitis (NEC) is a devastating disease caused by inflammation of the intestines observed primarily in premature and very low birth weight babies (VLBWB). The inflammation can result in an overwhelming infection which quickly becomes a medical emergency and often requires surgery as a life-saving measure. NEC affects between 4,000 - 6,000 VLBWB each year in the United States and carries a 30% mortality rate. Babies that do survive are often left with life-long intestinal complications and are also at increased risk for neurodevelopmental delay with cognitive, visual, and motor impairment. Treating and managing NEC costs over $5 billion annually in Neonatal Intensive Care Unit (NICU) expenditures.

There is currently no FDA-approved treatment for NEC.

About ST266

ST266 is a cell-free sterile biologic solution containing hundreds of proteins and other factors at physiologic levels. Extensive preclinical studies have shown that ST266's multiple components result in a variety of anti-inflammatory and neuroprotective responses. A drug master file has been submitted to the FDA, supporting all ST266 investigational new drug (IND) applications.

About Noveome Biotherapeutics, Inc.

Based in Pittsburgh, PA, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologic therapeutics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome has a robust pipeline developing novel treatments for various systemic and ophthalmic indications and has recently completed a Phase 1 study evaluating the safety of intravenously administered ST266 in the treatment of systemic inflammation associated with COVID-19. For more information, visit www.noveome.com.


These press releases may also interest you

at 20:05
Nutricosmetics Market Facts at a Glance- Companies: 10+ ? Including ActivInside, Borba LLC, Functionalab, Herbalife Nutrition Ltd.,...

at 20:00
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of...

at 18:00
ATC Healthcare Services, LLC ("ATC" the "Company") is making individuals aware of an incident that may affect the privacy of certain information. Although ATC is unaware of any actual or attempted misuse of such information, the Company is providing...

at 17:39
Reckitt is proud to provide the largest delivery of infant formula to the United States on three UPS flights from our world-class facility in Tuas, Singapore, facilitated by the White House's Operation Fly Formula initiative. With Reckitt's...

at 17:04
*  Fluzone® High-Dose Quadrivalent (Influenza Vaccine) and Flublok® Quadrivalent (Influenza Vaccine) are the only two flu vaccines proven to help prevent more cases of flu in older adults, compared to their standard-dose flu vaccine comparators as...

at 17:00
Lighthouse Health & Wellness is excited to announce that it has acquired Academy Hour, in a move that will further support the health and wellness of first responders nationwide. COMBINING FORCES FOR PUBLIC SAFETY'S GOOD The merging of Academy Hour...



News published on 24 may 2022 at 08:20 and distributed by: